AMNEAL PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $10.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $10.39M, a 25.60% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $8.82M, a 21.47% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $8.20M, a 13.76% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $8.22M, a 15.57% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $31.95M, a 15.07% increase from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $27.77M, a 3.53% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $26.82M, a 15.78% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $31.85M, a 12.09% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 2 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 5 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 8 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.39M 10-Q · filed 2026-08-06 | $19.21M 10-Q · filed 2026-08-06 | $27.41M derived: sum of 3 quarters · filed 2026-08-06 | $35.63M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $8.82M 10-Q · filed 2026-05-07 | $17.02M derived: sum of 2 quarters · filed 2026-05-07 | $25.24M derived: sum of 3 quarters · filed 2026-05-07 | $33.51M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $16.42M derived: sum of 2 quarters · filed 2026-02-27 | $24.70M derived: sum of 3 quarters · filed 2026-08-06 | $31.95M 10-K · filed 2026-02-27 | |||
| 2025-09-30 | $8.22M 10-Q · filed 2025-11-06 | $16.49M derived: sum of 2 quarters · filed 2026-08-06 | $23.75M 10-Q · filed 2025-11-06 | $30.96M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $8.27M 10-Q · filed 2026-08-06 | $15.53M 10-Q · filed 2026-08-06 | $22.74M derived: sum of 3 quarters · filed 2026-08-06 | $29.85M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $7.26M 10-Q · filed 2026-05-07 | $14.47M derived: sum of 2 quarters · filed 2026-05-07 | $21.58M derived: sum of 3 quarters · filed 2026-05-07 | $28.30M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.32M derived: sum of 2 quarters · filed 2026-02-27 | $21.05M derived: sum of 3 quarters · filed 2026-02-27 | $27.77M 10-K · filed 2026-02-27 | |||
| 2024-09-30 | $7.11M 10-Q · filed 2025-11-06 | $13.84M derived: sum of 2 quarters · filed 2025-11-06 | $20.56M 10-Q · filed 2025-11-06 | $26.53M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-06-30 | $6.72M 10-Q · filed 2025-08-07 | $13.45M 10-Q · filed 2025-08-07 | $19.42M derived: sum of 3 quarters · filed 2026-02-27 | $26.11M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2024-03-31 | $6.72M 10-Q · filed 2025-05-07 | $12.70M derived: sum of 2 quarters · filed 2026-02-27 | $19.39M derived: sum of 3 quarters · filed 2026-02-27 | $25.95M derived: sum of 4 quarters · filed 2026-02-27 | |||
| 2023-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $12.66M derived: sum of 2 quarters · filed 2026-02-27 | $19.23M derived: sum of 3 quarters · filed 2026-02-27 | $26.82M 10-K · filed 2026-02-27 | |||
| 2023-09-30 | $6.69M 10-Q · filed 2024-11-12 | $13.25M derived: sum of 2 quarters · filed 2024-11-12 | $20.85M 10-Q · filed 2024-11-12 | $28.68M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-06-30 | $6.56M 10-Q · filed 2024-08-09 | $14.16M 10-Q · filed 2024-08-09 | $21.99M derived: sum of 3 quarters · filed 2025-02-28 | $29.68M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2023-03-31 | $7.60M 10-Q · filed 2024-05-08 | $15.43M derived: sum of 2 quarters · filed 2025-02-28 | $23.12M derived: sum of 3 quarters · filed 2025-02-28 | $31.38M derived: sum of 4 quarters · filed 2025-02-28 | |||
| 2022-12-31 | $7.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $15.52M derived: sum of 2 quarters · filed 2025-02-28 | $23.78M derived: sum of 3 quarters · filed 2025-02-28 | $31.85M 10-K · filed 2025-02-28 | |||
| 2022-09-30 | $7.69M 10-Q · filed 2023-11-09 | $15.95M derived: sum of 2 quarters · filed 2023-11-09 | $24.02M 10-Q · filed 2023-11-09 | $31.76M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-06-30 | $8.26M 10-Q · filed 2023-08-08 | $16.33M 10-Q · filed 2023-08-08 | $24.07M derived: sum of 3 quarters · filed 2024-03-14 | $31.78M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2022-03-31 | $8.06M 10-Q · filed 2023-05-09 | $15.81M derived: sum of 2 quarters · filed 2024-03-14 | $23.52M derived: sum of 3 quarters · filed 2024-03-14 | $31.15M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $15.45M derived: sum of 2 quarters · filed 2024-03-14 | $23.08M derived: sum of 3 quarters · filed 2024-03-14 | $28.41M 10-K · filed 2024-03-14 | |||
| 2021-09-30 | $7.71M 10-Q · filed 2022-11-07 | $15.34M derived: sum of 2 quarters · filed 2022-11-07 | $20.67M 10-Q · filed 2022-11-07 | $25.80M derived: sum of 4 quarters · filed 2023-03-03 | |||
| 2021-06-30 | $7.63M 10-Q · filed 2022-08-08 | $12.96M 10-Q · filed 2022-08-08 | $18.09M derived: sum of 3 quarters · filed 2023-03-03 | $23.51M derived: sum of 4 quarters · filed 2023-03-03 | |||
| 2021-03-31 | $5.33M 10-Q · filed 2022-05-06 | $10.46M derived: sum of 2 quarters · filed 2023-03-03 | $15.88M derived: sum of 3 quarters · filed 2023-03-03 | $21.54M derived: sum of 4 quarters · filed 2023-03-03 | |||
| 2020-12-31 | $5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $10.55M derived: sum of 2 quarters · filed 2023-03-03 | $16.21M derived: sum of 3 quarters · filed 2023-03-03 | $20.75M 10-K · filed 2023-03-03 | |||
| 2020-09-30 | $5.42M 10-Q · filed 2021-11-08 | $11.08M derived: sum of 2 quarters · filed 2021-11-08 | $15.62M 10-Q · filed 2021-11-08 | $20.63M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $5.66M 10-Q · filed 2021-08-09 | $10.20M 10-Q · filed 2021-08-09 | $15.21M derived: sum of 3 quarters · filed 2022-03-01 | $21.31M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $4.54M 10-Q · filed 2021-05-07 | $9.55M derived: sum of 2 quarters · filed 2022-03-01 | $15.65M derived: sum of 3 quarters · filed 2022-03-01 | $21.87M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $11.11M derived: sum of 2 quarters · filed 2022-03-01 | $17.33M derived: sum of 3 quarters · filed 2022-03-01 | $21.68M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $6.09M 10-Q · filed 2020-11-06 | $12.32M derived: sum of 2 quarters · filed 2020-11-06 | $16.67M 10-Q · filed 2020-11-06 | ||||
| 2019-06-30 | $6.22M 10-Q · filed 2020-08-06 | $10.57M 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | $4.35M 10-Q · filed 2020-05-11 | ||||||
| 2018-12-31 | $8.84M 10-K · filed 2019-03-01 | ||||||
| 2018-09-30 | $5.23M 10-Q · filed 2018-11-07 | ||||||
| 2018-06-30 | $1.64M 10-Q · filed 2019-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |